Afya Limited Confirms Resolutions and Director Re-appointments at Annual Meeting

Afya ( (AFYA) ) just unveiled an update.

On June 24, 2025, Afya Limited announced the successful passing of resolutions during its Annual General Meeting. Key outcomes included the approval of financial statements for the fiscal year ending December 31, 2024, and the re-appointment of four independent directors: João Paulo Seibel de Faria, Vanessa Claro Lopes, Miguel Filisbino Pereira de Paula, and Marcelo Ken Suhara, each for a two-year term. This meeting underscores Afya’s commitment to maintaining strong governance and continuity in its leadership, which is crucial for its strategic positioning in the medical education industry.

The most recent analyst rating on (AFYA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Afya stock, see the AFYA Stock Forecast page.

Spark’s Take on AFYA Stock

According to Spark, TipRanks’ AI Analyst, AFYA is a Outperform.

Afya’s overall score reflects strong financial performance, marked by significant revenue and profitability growth. The positive momentum from the earnings call, despite some noted challenges, contributes positively. However, technical indicators suggest caution due to bearish signals, and valuation metrics show a balanced view.

To see Spark’s full report on AFYA stock, click here.

More about Afya

Afya Limited is a prominent medical education group in Brazil, known for its extensive number of medical school seats. The company offers a comprehensive physician-centric ecosystem that supports and empowers students and physicians from the start of their medical education through residency preparation, graduation, continuing medical education, and medical practice solutions to enhance healthcare services throughout their careers.

Average Trading Volume: 129,487

Technical Sentiment Signal: Hold

Current Market Cap: $1.56B

For a thorough assessment of AFYA stock, go to TipRanks’ Stock Analysis page.